RxDoctor Payments DataLook up a doctor →

Lena Bruce, MD

Family Practice · Santa Fe, TXNPI 1558322438

Payments from drug & device makers

$7,964in general payments, 2019–2025

Across 433 payments — averaging $18.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Lilly USA, LLC$1K
  • Amgen$833
  • Novo Nordisk$655
  • Bayer$650
  • AbbVie$341
  • plus $3K from 39 others

What the payments were for

  • Food & beverage$7,945100%
  • Education$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,964 in reported general payments places this provider in the 95th percentile of 646 family practice providers in Texas.

See all family practice providers in Texas

Medicare billing

Part B allowed, 2024
$34,467
Medicare patients
99
Services billed
316

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide83$108,000
Humira PenAdalimumab13$92,654
MounjaroTirzepatide52$62,817
FarxigaDapagliflozin Propanediol62$52,468
TrulicityDulaglutide33$45,707
JardianceEmpagliflozin39$41,008
RybelsusSemaglutide21$23,077
LinzessLinaclotide35$22,506
Repatha SureclickEvolocumab23$19,905
Bydureon BciseExenatide Microspheres17$15,645
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$13,856
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$13,804
Soliqua 100-33Insulin Glargine/Lixisenatide17$13,519
Repatha SyringeEvolocumab14$9,956
KerendiaFinerenone14$9,409

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$655$131,077104 claims
Lilly USA, LLCMounjaro, Trulicity$1,135$108,52485 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,235$68,75693 claims
Boehringer IngelheimJardiance, Combivent Respimat$238$47,38352 claims
AbbVieLinzess$341$22,50635 claims
GSKTrelegy Ellipta, Anoro Ellipta$71$21,00934 claims
BayerKerendia$650$9,40914 claims
MerckJanumet$204$6,20311 claims
IBSA Pharma Inc.Tirosint$17$2,84420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 646 family practice providers in Texas.

Other family practice in Santa Fe

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →